title: From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
abstract: New treatments-as immunotherapies and new antiangiogenic agents-are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Ettore
authors.initials: E
authors.lastname: D'Argento
authors.affiliation: Department of Medical Oncology, Humanitas Clinical and Research Center, Via Manzoni, 56, 20089, Rozzano, MI, Italy. sbrn.rossi85@gmail.com.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Rossi
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Schinzari
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Antonia
authors.initials: A
authors.lastname: Strippoli
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Basso
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Cassano
authors.affiliation: Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Barone
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D019233:Retreatment; D016896:Treatment Outcome
keywords: Antiangiogenic agents; Immunotherapy; Non-small-cell lung cancer; Second line